{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-106611","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.175825+00:00","generated_at":"2026-05-31T04:38:12.703344+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Korro Bio partners with Novo Nordisk for up to $530M in RNA editing deal for cardiometabolic targets","bullets":["Up to $530M in upfront, development, and commercial milestone payments plus tiered royalties and R&D funding.","Upfront fee of $10M for first target; potential additional upfront for second target if nominated.","Korro grants exclusive worldwide license to Novo Nordisk for two undisclosed cardiometabolic targets using OPERA platform.","Korro responsible for preclinical development; Novo Nordisk may advance programs through clinical studies.","Deal allows Korro to retain internal pipeline focus while expanding RNA editing to high-prevalence diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-106611","json":"https://secwatch.observer/filing/0000950170-24-106611.json","markdown":"https://secwatch.observer/filing/0000950170-24-106611.md","text":"https://secwatch.observer/filing/0000950170-24-106611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024106611/0000950170-24-106611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024106611/krro-20240913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:38:12.703344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}